These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 30953674

  • 1. Identification of a clinical compound losmapimod that blocks Lassa virus entry.
    Zhang X, Yan F, Tang K, Chen Q, Guo J, Zhu W, He S, Banadyga L, Qiu X, Guo Y.
    Antiviral Res; 2019 Jul; 167():68-77. PubMed ID: 30953674
    [Abstract] [Full Text] [Related]

  • 2. The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein.
    Zhang X, Tang K, Guo Y.
    Antiviral Res; 2020 Feb; 174():104701. PubMed ID: 31877348
    [Abstract] [Full Text] [Related]

  • 3. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
    Wang P, Liu Y, Zhang G, Wang S, Guo J, Cao J, Jia X, Zhang L, Xiao G, Wang W.
    J Virol; 2018 Aug 15; 92(16):. PubMed ID: 29899092
    [Abstract] [Full Text] [Related]

  • 4. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
    Torriani G, Trofimenko E, Mayor J, Fedeli C, Moreno H, Michel S, Heulot M, Chevalier N, Zimmer G, Shrestha N, Plattet P, Engler O, Rothenberger S, Widmann C, Kunz S.
    J Virol; 2019 Mar 15; 93(6):. PubMed ID: 30626681
    [Abstract] [Full Text] [Related]

  • 5. Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entry.
    Zhang Z, Takenaga T, Fehling SK, Igarashi M, Hirokawa T, Muramoto Y, Yamauchi K, Onishi C, Nakano M, Urata S, Groseth A, Strecker T, Noda T.
    J Virol; 2024 Jul 23; 98(7):e0071424. PubMed ID: 38809021
    [Abstract] [Full Text] [Related]

  • 6. Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein.
    Shankar S, Whitby LR, Casquilho-Gray HE, York J, Boger DL, Nunberg JH.
    J Virol; 2016 Aug 01; 90(15):6799-807. PubMed ID: 27194767
    [Abstract] [Full Text] [Related]

  • 7. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM.
    J Virol; 2019 Apr 15; 93(8):. PubMed ID: 30700611
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library.
    Lan X, Zhang Y, Jia X, Dong S, Liu Y, Zhang M, Guo J, Cao J, Guo Y, Xiao G, Wang W.
    Antiviral Res; 2022 Jan 15; 197():105230. PubMed ID: 34965446
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).
    Shao J, Huang Q, Liu X, Di D, Dileepan M, Brisse M, Ly H, Liang Y.
    J Virol; 2019 Nov 15; 93(22):. PubMed ID: 31462569
    [Abstract] [Full Text] [Related]

  • 13. Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments.
    Hulseberg CE, Fénéant L, Szymańska KM, White JM.
    mBio; 2018 Jan 02; 9(1):. PubMed ID: 29295909
    [Abstract] [Full Text] [Related]

  • 14. Identification of a macrocyclic compound targeting the lassa virus polymerase.
    Aida-Ficken V, Kelly JA, Chatterjee P, Jenks MH, McMullan LK, Albariño CG, Montgomery JM, Seley-Radtke KL, Spiropoulou CF, Flint M.
    Antiviral Res; 2024 Aug 02; 228():105923. PubMed ID: 38844175
    [Abstract] [Full Text] [Related]

  • 15. The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry.
    Fedeli C, Moreno H, Kunz S.
    Viruses; 2020 Aug 06; 12(8):. PubMed ID: 32781509
    [Abstract] [Full Text] [Related]

  • 16. Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan.
    Fedeli C, Torriani G, Galan-Navarro C, Moraz ML, Moreno H, Gerold G, Kunz S.
    J Virol; 2018 Mar 01; 92(5):. PubMed ID: 29237830
    [Abstract] [Full Text] [Related]

  • 17. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB.
    Sci Rep; 2015 Oct 12; 5():14775. PubMed ID: 26456301
    [Abstract] [Full Text] [Related]

  • 18. Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1.
    Wang MK, Ren T, Liu H, Lim SY, Lee K, Honko A, Zhou H, Dyall J, Hensley L, Gartin AK, Cunningham JM.
    PLoS Pathog; 2018 Sep 12; 14(9):e1007322. PubMed ID: 30265711
    [Abstract] [Full Text] [Related]

  • 19. 25-Hydroxycholesterol Inhibition of Lassa Virus Infection through Aberrant GP1 Glycosylation.
    Shrivastava-Ranjan P, Bergeron É, Chakrabarti AK, Albariño CG, Flint M, Nichol ST, Spiropoulou CF.
    mBio; 2016 Dec 20; 7(6):. PubMed ID: 27999160
    [Abstract] [Full Text] [Related]

  • 20. A potent Lassa virus antiviral targets an arenavirus virulence determinant.
    Madu IG, Files M, Gharaibeh DN, Moore AL, Jung KH, Gowen BB, Dai D, Jones KF, Tyavanagimatt SR, Burgeson JR, Korth MJ, Bedard KM, Iadonato SP, Amberg SM.
    PLoS Pathog; 2018 Dec 20; 14(12):e1007439. PubMed ID: 30576397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.